1
|
Marley SB, Gordon MY. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci (Lond) 2005; 109:13-25. [PMID: 15966868 DOI: 10.1042/cs20040336] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The biology of CML (chronic myeloid leukaemia) has been extensively investigated as the disease is a paradigm of neoplasms induced when a translocation results in expression of a novel fusion protein, in this instance p210(BCR-ABL). Although CML manifests itself principally as unregulated expansion of the myeloid lineage, the lesion is present in the stem cell population and it has long been assumed that disregulated stem cell kinetics must underlie the basic pathology of the disease. In this review, we present evidence that, in normal haemopoiesis, less primitive precursor cells retain considerable flexibility in their capacity to undergo self-renewal, allowing them to maintain lineage-specific homoeostasis without inflicting proliferative stress upon the stem cell population. This mechanism is dysregulated in CML and we have developed a self-renewal assay for CFU-GM (colony-forming unit-granulocyte/macrophage) which demonstrates that, in CML, the PI (proliferative index) of the myeloid progenitor cell population is increased. The ability to measure the PI as an endpoint of p210(BCR-ABL) expression gives considerable versatility to the in vitro investigation of putative therapeutic regimes in CML.
Collapse
MESH Headings
- Benzamides
- Cell Proliferation
- Fusion Proteins, bcr-abl/metabolism
- Hematopoietic Stem Cells/pathology
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Philadelphia Chromosome
- Piperazines/therapeutic use
- Protein Kinase Inhibitors/therapeutic use
- Pyrimidines/therapeutic use
- Signal Transduction
- Translocation, Genetic
Collapse
Affiliation(s)
- Stephen B Marley
- Department of Haematology, Imperial College Faculty of Medicine, DuCane Road, London W12 0NN, UK
| | | |
Collapse
|
2
|
Alenzi FQB, Wyse RKH, Altamimi WG. Apoptosis as a tool for therapeutic agents in haematological diseases. Expert Opin Biol Ther 2004; 4:407-20. [PMID: 15006734 DOI: 10.1517/14712598.4.3.407] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Apoptosis, an active mechanism of cell death, is an important process in many biological systems. Apoptosis is thought to contribute to many disease processes. This notion has raised expectations that therapeutic opportunities will naturally follow once a better understanding of these processes has been achieved. The regulation of apoptosis in normal and malignant haematological diseases represents an important therapeutic approach in the treatment of leukaemia and lymphoma. This review summarises recent developments in the clinical manipulation of apoptosis pathways in haematological therapy.
Collapse
Affiliation(s)
- Faris Q B Alenzi
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, King Faisal University, PO Box 1982, Dammam 31451, Kingdom of Saudi Arabia.
| | | | | |
Collapse
|
3
|
Marley SB, Lewis JL, Schneider H, Rudd CE, Gordon MY. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol 2004; 125:500-11. [PMID: 15142121 DOI: 10.1111/j.1365-2141.2004.04933.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We investigated the role of the phosphatidylinositol-3 kinase (PI-3K) pathway in regulating the proliferation of primary chronic myeloid leukaemia (CML) progenitor cells by using imatinib to inhibit the activity of p210(Bcr-Abl). The effect of imatinib on the expression of PI-3K pathway proteins was investigated by kinase assays and Western blotting; PI-3K was inhibited by wortmannin or LY294002, Jak2 by AG490 and farnesylation by FTI II; progenitor cell proliferation (self-renewal) was measured by growing myeloid colonies in vitro, then replating them to observe secondary colony formation. Suppression of p210(Bcr-Abl) with imatinib indirectly suppressed the activity of PI-3K and its downstream targets (Erk, Akt and p70S6 kinase), thereby implicating the PI-3K pathway in p210(Bcr-Abl)-mediated signalling in primary CML progenitor cells. The PI-3K inhibitors, wortmannin and LY294002 reproduced the differential effects of imatinib on normal and CML progenitor cell proliferation in vitro by increasing normal cell (P = 0.001) and reducing CML cell proliferation (P = 0.0003). This differential effect was attributable to dysregulated signalling by granulocyte colony-stimulating factor in CML. The responses of individual patient's cells to wortmannin correlated with their responses to imatinib (P = 0.004) but not their responses to AG490 (Jak2 kinase inhibitor) or FTI II (farnesyltransferase inhibitor). Individual responses to wortmannin also correlated with responses to interferon alpha (IFNalpha) (P = 0.016). Imatinib-resistant K562 cells were sensitive to LY294002. Inhibition of the PI-3K pathway may be common to imatinib and IFNalpha and reflect dysregulated cytokine signalling. As imatinib-resistant cells remained sensitive to wortmannin and LY294002, targeting the PI-3K pathway may provide an alternative therapy for imatinib-resistant patients.
Collapse
MESH Headings
- Alkyl and Aryl Transferases/antagonists & inhibitors
- Androstadienes/therapeutic use
- Antineoplastic Agents/therapeutic use
- Benzamides
- Blotting, Western/methods
- Cell Division/drug effects
- Cells, Cultured
- Chromones/therapeutic use
- Drug Therapy, Combination
- Farnesyltranstransferase
- Humans
- Imatinib Mesylate
- Interferon-gamma/therapeutic use
- Janus Kinase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Morpholines/therapeutic use
- Phosphatidylinositol 3-Kinases/analysis
- Phosphoinositide-3 Kinase Inhibitors
- Piperazines/therapeutic use
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Proto-Oncogene Proteins
- Pyrimidines/therapeutic use
- Signal Transduction/drug effects
- Stem Cells/drug effects
- Tyrphostins/therapeutic use
- Wortmannin
Collapse
Affiliation(s)
- S B Marley
- Department of Haematology, Imperial College Faculty of Medicine, London, UK
| | | | | | | | | |
Collapse
|
4
|
Abstract
Apoptosis, an active mechanism of cell death, is of central importance in many biological scenarios. Research in this area has the potential to contribute to our understanding of many diseases and raises several potential therapeutic opportunities. Given this potential and the speed with which our understanding of this field has advanced over recent years, it is timely to introduce the clinician to the background on which the clinical implications of this research will be built. This review begins with contrasting apoptosis with the other mechanism of cell death, necrosis, and then outlines the features by which apoptosis may be recognised. With a view to understanding the level at which this process may be involved in disease and therapeutics, it is important to be aware of the basic mechanistic features of the induction and execution of apoptosis. In this, surface molecules such as CD95 (Fas) and the cascade of intracellular enzymes involved at many levels in apoptosis, the caspases, are of central importance. In all this, the mitochondrion is crucial to the induction of apoptosis and the regulation of the whole process. In the last part of this review, we attempt to draw out the clinical relevance of all this information. It is clear that apoptosis has an important role in the pathophysiology of malignancy, particularly with respect to haematological cancers, but also other oncological diseases. Apoptosis is also very important in autoimmune disease and viral infection. Finally, it is clear that apoptosis may be manipulated therapeutically to the benefit of patients in various scenarios. This is clearly an exciting area for future development, but one which clearly depends on a thorough mechanistic understanding.
Collapse
MESH Headings
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/therapeutic use
- Apoptosis/drug effects
- Apoptosis/genetics
- Apoptosis/physiology
- Calorimetry
- Caspases/analysis
- Caspases/metabolism
- Cell Death/physiology
- Cell Transformation, Neoplastic
- Cytokines/physiology
- Drug Resistance, Neoplasm
- Flow Cytometry
- Forecasting
- Genes, bcl-2
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Mitochondria/physiology
- Necrosis
- Neoplasms/drug therapy
- Neoplasms/pathology
- Neoplasms/physiopathology
- Phagocytosis
- Research
- Rituximab
- Spectrophotometry
- fas Receptor
Collapse
Affiliation(s)
- Faris Q Alenzi
- Clinical Laboratory Science, School of Medicine and Medical Sciences, King Faisal University, Dammam, Saudi Arabia
| | | |
Collapse
|
5
|
Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003; 101:4583-8. [PMID: 12576338 DOI: 10.1182/blood-2002-10-3011] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BCR-ABL fusion oncogene is the molecular hallmark of chronic myelogenous leukemia (CML), a condition characterized by a progression from a chronic to acute phase leukemia because of secondary genetic events, the nature of which remains largely unknown. Here, we report that the expression of the p210 BCR-ABL fusion protein leads to a down-regulation of BRCA1 protein, a gene product involved in the maintenance of genome integrity. BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. Similarly, stable transfection-enforced expression of p210 protein in established hematopoietic cell lines leads to severe BRCA1 depletion. The lack of significant change in BRCA1 mRNA level in cells expressing p210 supports the hypothesis that the regulation of BRCA1 protein level occurs after transcription. It is abolished on exposure of the cells to STI571 and by mutation in the adenosine triphosphate (ATP) pocket of p210 and thus seems to require the tyrosine kinase activity of BCR-ABL. Cell lines expressing high levels of BCR-ABL display an increased rate of sister chromatid exchange and chromosome aberrations after ionizing radiation. These findings reveal a novel link between the oncoprotein BCR-ABL and the tumor-suppressor protein BRCA1.
Collapse
Affiliation(s)
- Eric Deutsch
- Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002; 21:8591-604. [PMID: 12476306 DOI: 10.1038/sj.onc.1206087] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BCR/ABL regulates cell proliferation, apoptosis, differentiation and adhesion. In addition, BCR/ABL can induce resistance to cytostatic drugs and irradiation by modulation of DNA repair mechanisms, cell cycle checkpoints and Bcl-2 protein family members. Upon DNA damage BCR/ABL not only enhances reparation of DNA lesions (e.g. homologous recombination repair), but also prolongs activation of cell cycle checkpoints (e.g. G2/M) providing more time for repair of otherwise lethal lesions. Moreover, by modification of anti-apoptotic members of the Bcl-2 family (e.g. upregulation of Bcl-x(L)) BCR/ABL provides a cytoplasmic 'umbrella' protecting mitochondria from the 'rain' of apoptotic signals coming from the damaged DNA in the nucleus, thus preventing release of cytochrome c and activation of caspases. The unrepaired and/or aberrantly repaired (but not lethal) DNA lesions resulting from spontaneous and/or drug-induced damage can accumulate in BCR/ABL-transformed cells leading to genomic instability and malignant progression of the disease. Inhibition of BCR/ABL kinase activity by STI571 (Gleevec, imatinib mesylate) reverses drug resistance and, in combination with standard chemotherapeutics can exert strong anti-leukemia effect.
Collapse
Affiliation(s)
- Tomasz Skorski
- Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, PA 19122, USA.
| |
Collapse
|
7
|
Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001; 113:11-23. [PMID: 11328274 DOI: 10.1046/j.1365-2141.2001.02558.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
MESH Headings
- Animals
- Apoptosis/genetics
- Benzamides
- Cell Adhesion/genetics
- Cell Cycle
- Cell Line, Transformed
- Clinical Trials as Topic
- Cytoskeleton/pathology
- Enzyme Inhibitors/therapeutic use
- Fusion Proteins, bcr-abl
- Genes, abl
- Growth Substances/metabolism
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Mice
- Mice, Transgenic
- Models, Animal
- Philadelphia Chromosome
- Piperazines/therapeutic use
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Pyrimidines/therapeutic use
- Signal Transduction/genetics
- Stem Cells
- Telomere
Collapse
Affiliation(s)
- D T Holyoake
- Academic Transfusion Medicine Unit, Department of Medicine, Royal Infirmary, Glasgow, UK.
| |
Collapse
|
8
|
Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S, M'Kacher R, Rasy SD, Eschwege F, Vainchenker W, Turhan AG, Bourhis J. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001; 97:2084-90. [PMID: 11264175 DOI: 10.1182/blood.v97.7.2084] [Citation(s) in RCA: 127] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This study demonstrates in both stable and inducible BCR-ABL-expressing hematopoietic cells a down-regulation of the major mammalian DNA repair protein DNA-PKcs by BCR-ABL. Similar results were found in BCR-ABL CD34(+) cells from patients with chronic myelogenous leukemia (CML). DNA-PKcs down-regulation is a proteasome-dependent degradation that requires tyrosine kinase activity and is associated with a marked DNA repair deficiency along with increased sensitivity to ionizing radiation. The conjunction of a major DNA repair deficiency and a resistance to apoptosis, both induced by BCR-ABL, provides a new mechanism to explain how secondary genetic alterations can accumulate in CML, eventually leading to blast crisis. The down-regulation of DNA-PKcs was reversible in CD34(+) CML cells suggesting that this approach might offer a novel and powerful therapeutic strategy in this disease, especially to delay the blast crisis. (Blood. 2001;97:2084-2090)
Collapse
MESH Headings
- Acetylcysteine/analogs & derivatives
- Acetylcysteine/pharmacology
- Animals
- Apoptosis/genetics
- Apoptosis/radiation effects
- Blast Crisis/genetics
- Child
- Cysteine Endopeptidases/metabolism
- DNA Repair/genetics
- DNA, Neoplasm/metabolism
- DNA-Activated Protein Kinase
- DNA-Binding Proteins
- Enzyme Induction
- Enzyme Inhibitors/pharmacology
- Fusion Proteins, bcr-abl/physiology
- Gene Expression Regulation, Leukemic
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Mice
- Multienzyme Complexes/antagonists & inhibitors
- Multienzyme Complexes/metabolism
- Neuroblastoma/pathology
- Nuclear Proteins
- Oligopeptides/pharmacology
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Protease Inhibitors/pharmacology
- Proteasome Endopeptidase Complex
- Protein Serine-Threonine Kinases/biosynthesis
- Protein Serine-Threonine Kinases/genetics
- Recombinant Fusion Proteins/physiology
- Reverse Transcriptase Polymerase Chain Reaction
- Transfection
- Tumor Cells, Cultured/enzymology
- Tumor Stem Cell Assay
- Tyrphostins/pharmacology
Collapse
Affiliation(s)
- E Deutsch
- UPRES EA 27-10 Radiosensibilité-Radiocarcinogenèse Humaine and METSI, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
|
10
|
|
11
|
Epperly MW, Bray JA, Esocobar P, Bigbee WL, Watkins S, Greenberger JS. Overexpression of the human manganese superoxide dismutase (MnSOD) transgene in subclones of murine hematopoietic progenitor cell line 32D cl 3 decreases irradiation-induced apoptosis but does not alter G2/M or G1/S phase cell cycle arrest. RADIATION ONCOLOGY INVESTIGATIONS 2000; 7:331-42. [PMID: 10644056 DOI: 10.1002/(sici)1520-6823(1999)7:6<331::aid-roi3>3.0.co;2-m] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To determine whether overexpression of the human MnSOD transgene protected 32D cl 3 hematopoietic progenitor cells from ionizing irradiation, 32D cl 3 cells were co-electroporated with the pRK5 plasmid containing the human MnSOD transgene and SV2-neo plasmid with G418-resistant colonies selected. Two clones (1F2 and 2C6) were identified to overexpress the human MnSOD transgene by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and increased biochemical activity. Measurement of irradiation-induced damage was determined in cells removed from G418 for 1 week before irradiation. Irradiation survival curves, apoptosis tunnel assay, and Comet assay was performed. Cell cycle distribution was determined for each line at 0, 1, 3, 6, 24, and 48 hr after 500 cGy by fixing the cells in 70% ethanol, staining with propidium iodide, and analysis by flow cytometer. Biochemical MnSOD activity in U/mg protein was 2.6 for 32D cl 3 and significantly elevated to 8.4 and 6.6 (P < 0.001) U/mg protein for subclones 1F2 and 2C6, respectively. Irradiation survival curves demonstrated an increased shoulder on the irradiation survival curve for 1F2 and 2C6 cells with an n of 4.95 +/- 0.48 (P = 0.042) and 4.95 +/- 0.13 (P = 0.011), compared with 2.77 +/- 0.20 for 32D cl 3. A higher percent of 32D cl 3 cells demonstrated apoptosis at 24 and 48 hr after 1,000 cGy irradiation, compared with 1F2 and 2C6 cells (at 24 hr, 29.37% +/- 2.01% of 32D cl 3 cells were apoptotic compared with 5.21 +/- 2.61 (P = 0.018) and 5.27 +/- 2.58 (P = 0.004) for 1F2 and 2C6, respectively). Significantly more DNA strand breaks were detected by Comet assay in 32D cl 3 cells (Comet length at 600 cGy of 103.4 +/- 50.3 units, compared with 69.7 +/- 36.3 (P < 0.001) and 48.9 +/- 27.5 (P < 0.001) for 1F2 and 2C6, respectively). In contrast, irradiation-induced cell cycle arrest was similar between the cell lines with a G2/M phase arrest at 6 hr and a G1/S phase arrest at 24 and 48 hr after irradiation. While overexpression of MnSOD increases the shoulder on the irradiation survival curve of 32D cl 3 cells, decreases irradiation-induced apoptosis, and DNA strand breaks by Comet assay, irradiation-induced alterations in cell cycle distribution were not significantly altered. These 32D cl 3 subclonal lines overexpressing MnSOD provide a potentially valuable system with which to study the mechanism of irradiation-induced cell cycle arrest separate from irradiation-induced apoptosis.
Collapse
Affiliation(s)
- M W Epperly
- Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
| | | | | | | | | | | |
Collapse
|
12
|
Santucci MA, Ripalti A, di Paola MC, Mianulli AM, Iacurti E, Campanini F, Gamberi B, Tura S. Procedure for the quantitation of Gadd45 expression levels in clonal hematopoietic progenitor cells by competitive polymerase chain reaction. Clin Biochem 1999; 32:1-8. [PMID: 10074885 DOI: 10.1016/s0009-9120(98)00092-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The growth arrest and DNA damage-inducible (gadd) genes represent a family of stress-inducible genes that are coordinately regulated at transcriptional level. Gadd45, in particular, has been linked to a p53-dependent inducible network required for regulated transition from G1 to S phase of cell cycle following genotoxic insult and growth arrest treatments and has seemingly a pivotal role in DNA repair. DESIGN AND METHODS Here we show that competitive polymerase chain reaction (PCR) is an adequate method to quantitate gadd45 expression levels in hematopoietic progenitor cell line 32D, whose constitutive gene expression is very low. RESULTS The sensitivity and reproducibility of our strategy support its usefulness for clinical purposes, to assess the DNA repair capacity of highly purified early myeloid progenitors, whose failure may be responsible for either short-term chemotherapy side effects (bone marrow hypoplasia and peripheral blood cytopenia) or long-term consequences of antiblastic drugs (leukemia and myelodysplasia).
Collapse
Affiliation(s)
- M A Santucci
- Laboratory of Molecular and Cellular Biology, Institute of Hematology and Clinical Oncology L. e A. Seràgnoli, University of Bologna, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Cosset JM, Socié G, Girinsky T, Dubray B, Fourquet A, Gluckman E. Radiobiological and clinical bases for total body irradiation in the leukemias and lymphomas. Semin Radiat Oncol 1995. [DOI: 10.1016/s1053-4296(05)80028-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995; 91:387-93. [PMID: 8547080 DOI: 10.1111/j.1365-2141.1995.tb05308.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Inhibition of apoptosis (genetically programmed active cell death) by p210 BCR-ABL expression is a mechanism that might contribute to clonal expansion in chronic myeloid leukaemia (CML). Since cell death following exposure to ionizing radiation and many chemotherapeutic agents can occur by the apoptotic pathway, inhibition of apoptosis would be expected to confer a relative resistance to these treatments. Similarly, cells deprived of growth factors in vitro die by apoptosis, and inhibition of apoptosis would therefore be expected to allow cells to survive better in growth factor-deprived conditions. We found that the survival of normal and CML myeloid progenitors was the same after in vitro incubation in deprived conditions and after treatment with X-irradiation or glucocorticoids. We also found that mature cells in colonies produced by CML progenitors (CFU-GM) did not survive better than those produced by normal progenitor cells. Flow cytometric analysis of propidium iodide-stained cells provided a direct indication that the degree of apoptosis may correspond to the degree of deprivation. These results suggest that inhibition of apoptosis may not be the primary mechanism whereby BCR-ABL influences the expansion of the malignant clone in CML.
Collapse
Affiliation(s)
- T A Amos
- Leukaemia Research Fund Centre for Adult Leukaemia, Royal Postgraduate Medical School, London
| | | | | | | | | | | |
Collapse
|
15
|
Pileri S, Poggi S, Sabattini E, Santucci S, Melilli G, Falini B, Tosi P. Apoptosis as programmed cell death (PCD): Cupio dissolvi in cell life. ACTA ACUST UNITED AC 1994. [DOI: 10.1016/s0968-6053(06)80009-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Epperly MW, Santucci MA, Reed JC, Shields D, Halloran A, Greenberger JS. Expression of the human BCL-2 transgene increases the radiation resistance of a hematopoietic progenitor cell line. ACTA ACUST UNITED AC 1994. [DOI: 10.1002/roi.2970020204] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|